Many drugmakers suffered at the height of the pandemic as sales volumes for prescription drugs decreased. Pharma giant Merck (NYSE: MRK) was one of those companies that saw financial results took a hit due to the outbreak. As a result, the company's shares have significantly lagged the market in the past year.
However, a couple of recent developments could help Merck turn things around. With that as a backdrop, let's look at Merck's overall business and decide whether it is worth buying the company's shares today.
Source Fool.com